Cambridge Healthtech Institute's Seventh Annual

Bispecific Antibody Therapeutics

( 双特异性抗体疗法 )

Engineering Multi-Specificity

2018年1月11日 - 12日

Cambridge Healthtech Institute's Bispecific Antibody Therapeutics conference explores the challenges of engineering multi-specificity to achieve more effective therapies that bind to at least two molecular targets simultaneously. These next-generation antibody formats are showing efficacy in the efforts to conquer cancer and other diseases. Case studies will highlight novel engineering approaches that address safety, stability, enhanced targeting, and manufacturability, as the conference examines current developments, and future directions for these promising molecules.

Preliminary Agenda

Creating Next-Generation Therapies

The Rise of Bispecific Antibodies as Drugs

Paul Carter, Ph.D., Staff Scientist and Senior Director, Antibody Engineering, Genentech, Inc.

Non-Engineered Multispecific Antibodies

Marie Kosco-Vilbois, Ph.D., CSO, NovImmune SA

Examples of Development Strategies for Next-Generation Therapeutics

Nicola Beaucamp, Ph.D., Head, Process Research, Pharma Research and Early Development, Roche Innovation Center, Roche Diagnostics GmbH

Design and Evaluation of Next-Generation Biologics for Cancer Immunotherapy

Christopher Smith, Ph.D., Senior Scientific Consultant, Biologics, Genedata

Molecular Breakthrough for Enhancing Multi-Specificities

Co-Stimulation of Immune Cells in the Tumor Microenvironment via Bispecific DART and TRIDENT Molecules

Gundo Diedrich, Ph.D., Associate Director, Antibody Engineering, MacroGenics, Inc.

From the Bench to the Clinic: Developing Next-Generation ADAPTIR Molecules

David Bienvenue, Ph.D., Senior Director, Protein Sciences, Aptevo Therapeutics

Engineering IgM CH2 Domain as a Versatile Building Block for the Construction of Various Multispecific Antibodies 

Jijie Gu, Ph.D., Research Fellow and Function Head, AbbVie Bioresearch Center

Engineering Improved Properties

Identification and Quantitation of DuoBody Bispecific IgG1 Using Mass Spectrometry and Automated Data Processing and Analysis Workflow

Ewald Van den Bremer, Ph.D., Senior Scientist, Genmab A/S

An IgM-based Bispecific Platform for Enhanced T-Cell and Complement Dependent Cytotoxicity on Low Antigen Expressing Cells

Ramesh Baliga, Ph.D., Vice President, Discovery Biology, IGM Biosciences, Inc.

A Novel Trifunctional Antibody Combining PD-1/PD-L1 Blockade and Targeting of a Tumor-Specific Carbohydrate Antigen

Christoph Goletz, Associate Director, Immunomodulation, Glycotope GmbH

* 活动内容有可能不事先告知作更动及调整。